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Methodological refinement of 
Aldara-induced psoriasiform 
dermatitis model in mice
Szabina Horváth1, Rita Komlódi2, Anikó Perkecz2, Erika Pintér2,3, Rolland Gyulai1 & 
Ágnes Kemény  2,3,4
Imiquimod (IMQ)-induced skin inflammation is currently the most widely accepted psoriasis animal 
model, however, it features several limitations. We have modified the IMQ-model to minimize its 
systemic effects towards effectively maintaining the characteristic skin reactions. The original protocol 
(OP) uses 62.5 mg Aldara cream (or vaseline) on the shaved back skin of mice for 4 days. In contrast, 
in our modified protocol (MP) 25 mg Aldara and vaseline are applied simultaneously in separate Finn 
chambers over the dorsal skin of mice. In both the OP and MP groups, histology showed unequivocal 
hallmarks of psoriasiform dermatitis. Additionally, skin scaling and blood perfusion values were similar. 
While Aldara elicited significantly increased skin thickness in the MP group, significant weight loss, 
spleen enlargement, increased inflammatory cytokine levels in plasma, and treatment related death 
were only observed in the OP group. Our new method reproduces psoriatic skin alterations highlighting 
considerably reduced systemic inflammatory reactions. Possessing psoriasiform and control skin areas 
on the same mouse also reduces inter-individual differences. Additionally, the new method permits 
prolonged IMQ treatment studies to mimic the chronic nature of psoriasis. Finally, our experimental 
approach may also be used in other mouse models, to prevent the undesired systemic effects of 
topically applied drugs.
Aldara (5% imiquimod)-induced acute skin inflammation became the most widely used animal model of pso-
riasis since it was first published in 20091. In this model, 62.5 mg Aldara is smeared onto the shaved dorsal skin 
of mice for 5 or 6 days to induce scaly skin lesions resembling plaque type psoriasis. While the model does not 
exactly recapitulate human psoriasis2, imiquimod treatment of mouse skin can exert specific cytokine expression 
patterns, histopathological alterations and cellular infiltrates similar to what is observed in psoriatic patients3. 
Imiquimod is able to activate proinflammatory signaling pathways via the ligation of TLR7/8 upon dermal den-
dritic cells (DDCs), however, it is likely that other mechanisms such as NLRP1 inflammasome activation (pyrop-
tosis)4, direct activation of TRPA1 non-selective cation channels located on immune cells and peripheral nerve 
endings5 also contributes to its proinflammatory effects. While it is generally accepted that IL-17 producing Th17 
cells are the main cell type responsible for the development of the skin inflammation, other cells, such as subsets 
of the γδT17 cells also contribute to the immune reaction6.
Aldara-induced skin inflammation has several advantages compared to previous models of psoriasis, includ-
ing rapid and reproducible skin response. Animals do not need pathogen free conditions, as seen in xenotrans-
plantation models, and it is relatively inexpensive7. On the other hand, this model possesses several limitations. 
Among these, the overuse of the Aldara cream and its ingestion is the most problematic since it can cause severe 
systemic inflammation indicated by splenomegaly, worsened general condition and untimely death of the ani-
mals8. This can contribute to the phenotypic variability observed in this model and it may likely be the reason for 
the different treatment regimens applied by various authors1,9,10.
Therefore, our aim was to refine the Aldara-induced psoriasiform inflammatory model to determine the opti-
mal dose of cream with maintained pathological alterations present in psoriasis and to eliminate systemic effects 
by reducing the possibility of ingestion and direct scratching of the treated dorsal skin.
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Results
Clinical signs of Aldara-induced skin inflammation. Clinical signs of psoriasis, such as skin thicken-
ing, erythema, and scaling were consistently observed in Aldara treated animals, however, they were not seen in 
vaseline-treated skin using the two different disease induction techniques in C57BL/6 mice (Fig. 1a). Erythema 
developed following the second treatment using Aldara, and soon thereafter, scaling appeared on the third day 
which continually increased in severity up to the end of the experiment in both OP and MP group (Fig. 1a).
Similar blood perfusion results in OP and MP treatment groups. Aldara treatment induced elevated 
microcirculation in the dorsal skin compared to the vaseline-treated sites, represented by the red areas on the 
color pictures assessed by LASCA laser Speckle instrument (Fig. 1b). Significant increase in dorsal skin blood 
flow was observed using both Aldara treatment techniques compared to the control group or skin area, reaching 
maximal responses on day 3. More pronounced differences were measured between vaseline- or Aldara-treated 
sites in MP group on day 2 and 3. The same percent change values are noted in the Aldara-induced microcircula-
tion in both OP and MP groups (Fig. 1d).
Aldara treatment induced significantly higher back skin thickness in the MP group. Application 
of Aldara cream significantly increased the thickness of dorsal skin compared to vaseline treated control mice 
Figure 1. Comparison of functional parameters in Aldara-induced psoriasiform dermatitis using original 
and modified protocols. (a) Clinical signs of topical Aldara treatment on C57BL/6 mice throughout the 5 day 
experiment. 62.5 mg vaseline (OP group - Vaseline) or Aldara (OP group - Aldara) was applied to the back 
skin of mice. 25–25 mg vaseline (V) or Aldara (A) was applied to the shaved back skin of animals using Finn 
chambers (MP group). (b) Representative images of blood perfusion changes on C57BL/6 mice dorsal skin 
induced by topical application of vaseline or Aldara in the OP group and in the MP group using Finn chambers. 
(c) Percent increase of back skin thickness after vaseline or Aldara treatment in OP or MP groups compared to 
day 0 baseline values. Data are mean ± SEM for n = 15/group. ***p < 0.001 vaseline vs. Aldara-treated sites, 
###p < 0.001 Aldara-treated OP group vs. Aldara-treated MP group, based on repeated measures 2-way ANOVA 
followed by Bonferroni’s post hoc test. (d) Percent change of blood perfusion in dorsal skin after vaseline or 
Aldara treatment compared to the day 0 values. Data are mean ± SEM for n = 15/group. *p < 0.05; **p < 0.01 
vaseline vs. Aldara-treated sites, based on repeated measures 2-way ANOVA followed by Bonferroni’s post 
hoc test. (e) Skin scaling scores after vaseline of Aldara treatment in OP group or MP group. Scaling was 
graded from 0 to 4 (0: absent to 4: severe). Data are mean ± SEM for n = 7–15/group. ***p < 0.001 vaseline vs. 
Aldara-treated sites, based on 2-way ANOVA followed by Bonferroni’s post hoc test. OP: original protocol, MP: 
modified protocol.
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in the OP group from day 3, while in the MP group a significant difference was observed following the first 
treatment. Aldara (IMQ) generated skin edema/infiltration in both the OP group and MP group, resulted in a 
constant increase until the end of the experiment, ultimately attaining a maximum value of 60% or 86% in OP or 
MP group, respectively. Dorsal skin swelling/infiltration was significantly higher in the Aldara-treated MP group 
when compared to the OP group on each day of experiment (Fig. 1c).
No significant difference was observed in skin scaling of OP and MP treatment groups. Skin 
scaling was formed only on the Aldara-treated dorsal skin of the MP group, but not on the vaseline-treated skin 
areas. Increasing skin scaling scores were observed throughout the 5-day experiment in the Aldara-treated site 
and there was no significant difference between the OP and MP groups (Fig. 1e).
Histological analysis of Aldara-induced dermatitis in OP or MP groups. Histological sections of 
Aldara-treated skin obtained from the “whole back skin” model or “Finn chamber” model clearly showed typical 
alterations present in psoriasis (keratinocytes hyperproliferation, hyperkeratosis, parakeratosis, Munro micro-
abscesses) in both experimental groups (Fig. 2). Accumulation of neutrofils in the epidermis produced several 
Munro microabscesses following Aldara treatment (Fig. 2c,d open arrows). Tortured, dilated capillaries appeared 
in the dermal region of skin samples in both experimental paradigms (Fig. 2c,d black arrows). T-cell infiltration 
was also observable in the dermis of Aldara-treated skin samples of OP or MP groups (Fig. 2c,d insert, white 
arrows). Histopathological scoring assessing characteristic parameters in psoriasis (Munro’s microabscesses and 
thickness of epidermal layer) was not significant between Aldara-treated skin samples of OP group when com-
pared to the MP group (Fig. 2e,f).
Similar Ki-67 and CD11b expression pattern in OP or MP groups. Distribution of Ki-67+ cells in the 
stratum basale of Aldara-treated skin samples of OP or MP groups indicate similar cell proliferation rate induced 
by the conventional or the modified methods (Fig. 3a,b). CD11b+ dermal dendritic cells were present in higher 
number following Aldara treatment in both experimental groups (Fig. 3c,d).
Reduced systemic inflammatory response in the MP group. An elevation in the percentile change 
of body weight was detected in the vaseline-treated control OP group while significant weight loss was registered 
throughout the 5-day experiment in the Aldara-treated OP and MP groups. Body weight loss was more remark-
able in the “whole back” model group compared to the “Finn chamber” model group after the first, second and 
third Aldara treatments (Fig. 4a). Spleen weights were at or about 0.09 gram in the vaseline-treated OP group at 
the end of the experiment and we found significantly enlarged spleen tissues following the fourth day of Aldara 
treatment in the OP group (0.16 gram). The average spleen tissue weight in the MP group (“Finn chamber” 
model) was similar to the vaseline-treated OP group (0.11 gram) (Fig. 4b).
Plasma concentration of inflammatory cytokines is only increased in the OP group. IL-1β and 
IFN-α cytokine concentrations were increased (p < 0.05) in the peripheral blood samples of mice in the OP 
group 6 hrs following the first Aldara treatment compared to the vehicle-treated group. Aldara did not enhance 
the levels of these cytokines in the MP group. TNF-α concentration was elevated in the case of Aldara-treated OP 
group compared to the MP group following the first treatment, however, significant differences were not detected 
between the Aldara-treated and the vaseline-treated control groups (Fig. 5).
Discussion
Since its first introduction in 2009, the IMQ-induced psoriasis mice model has become the most widely used 
animal study in the field of psoriasis. In their recent review, Hawkes et al. relates to the exponentially increas-
ing number of IMQ-model papers as the ‘Snowballing Literature on Imiquimod-Induced Skin Inflammation in 
Mice’7. The popularity of the method is likely associated with several advantages it offers to scientists: it is easy 
to use, provides quick results, it is versatile (can be combined with other methods, such as genetically modified 
animals), and it is relatively inexpensive. However, the method has several drawbacks, which require special 
attention and consideration when interpreting scientific data. Among these, as noted in the paper, Hawkes et 
al., first lists the ‘unintended consequences of topical treatment’, which highlights systemic side effects of imi-
quimod application. In their original paper, van der Fits et al. describes a significant spleen enlargement with an 
approximately 2-fold weight increase in the animals following 5 to 6 days of IMQ treatment1. Indeed, in most 
publications, IMQ-treated animals develop splenomegaly during the experimental procedure, clearly demon-
strating how topical treatment of mice with IMQ results in systemic effects8,11,12. Moreover, topical IMQ treatment 
in mice leads to robust systemic inflammation (marked by elevated inflammatory cytokine levels in blood) and 
severe dehydration (often requiring the administration of subcutaneous fluids). Although this phenomenon is 
frequently overlooked or disregarded when interpreting data generated by the imiquimod model, systemic dis-
ease may significantly influence the results. Dehydration, for example, causes significant changes in skin struc-
ture, leading to thinner, tighter and flakier skin. Systemic and cutaneous dehydration may also severely impact 
skin barrier and immune functions, and thus, may substantially influence the outcome of the experiments. Since 
in the traditional model IMQ-treated animals will develop these symptoms to varying extent, while the control 
mice will not, resulting in a very high likelihood for inherent experimental bias.
Systemic symptoms are likely associated with at least two factors. First, in mice, the area of treated skin in the 
traditional model is considerably large, approximately 15% of the total body surface area13. Imiquimod treatment 
over such a large skin area possibly leads to general symptoms, and is also observed in humans14,15. Secondly, 
the grooming behavior of the animals results in the ingestion of imiquimod, generating type I IFN induction 
and activation in the gut, and consequently, leading to systemic responses8. This can be more problematic if 
control and treated animals are co-housed, as in this case, control animals may also ingest a significant amount 
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of imiquimod from their littermates. Moreover, once ingested, imiquimod tends to modify the gut microbiome, 
which can have substantial consequences regarding (skin) immune function16–18. While ingestion of imiquimod 
can be avoided by housing the animals separately, and with the use of Elizabethan collars to prevent self-licking, 
the large treated surface area remains a potential experimental pitfall.
In reference to our research, we are introducing a new method for the induction of psoriasiform dermatitis 
in mice using Finn chambers. This new technique proved to be sufficient to elicit skin reactions such as edema, 
infiltration, scaling, increased blood perfusion, and psoriasiform histopathological alterations, similar to the 
classical imiquimod model. However, our new method leads to considerably reduced systemic inflammatory 
reactions in the animals, as indicated by the moderate splenomegaly and weight loss, as well as little or no signif-
icant increase of IL-1β, TNF-α and IFN-α concentrations in the blood of the animals. We assume the decreased 
systemic response is due both to the reduced IMQ-treated skin area and to the prevention of oral intake. A further 
Figure 2. Comparison of histological alterations following Aldara- or vaseline-treatment on the dorsal skin 
of C57BL/6 mice using OP or MP. Vaseline-treated control skin of OP group (a) or MP group (b) at 200x 
magnification. Aldara-treated skin of OP group (c) or MP group (d) at 200x magnification. Open arrow: 
Munro’s microabscesses, black arrow: dilated capillaries. White arrows in the inserts indicate T-cell infiltration 
in the dermis. Thickness of epidermal layer (e) and number of Munro’s microabscesses (f) throughout the 
sections after different treatments. Hematoxylin-eosin staining. Data are mean ± SEM for n = 5/group. 
**p < 0.01 ***p < 0.001 vaseline vs. Aldara-treated sites, based on one-way ANOVA followed by Bonferroni’s 
post hoc test. OP: original protocol, MP: modified protocol.
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advantage of the method is the psoriasiform and the control skin areas are on the same mice. This fact decreases 
the likelihood of inter-animal differences and ensures the model is even more cost-effective. On the other hand, 
one can argue, in consideration of this method, imiquimod may elicit some systemic effects, which may theo-
retically influence the control data. If this is a potential concern for the experimental design, we suggest using 
separate animals as controls.
Figure 3. Comparison of Ki-67 or CD11b immunoreactivity of Aldara-treated dorsal skin samples of C57BL/6 
mice using OP or MP. Nuclear proliferation marker Ki-67 immunostaining on OP (a) and MP (b) dorsal skin 
tissue samples at 400x magnification. Dermal dendritic cells were labelled with anti-CD11b antibody on OP (c) 
and MP samples (d) at 400x magnification.
Figure 4. Modified protocol reduced the systemic effect of IMQ treatment in C57BL/6 mice. (a) Percent change 
of body weight after vaseline or Aldara treatment using two different methods. Data were expressed as percent 
change of body weight compared with day 0 baseline initial values. Data are mean ± SEM for n = 15/group. 
#p < 0.05; ##p < 0.01; ###p < 0.001 Aldara-treated OP group vs. Aldara-treated MP group, ***p < 0.001 vaseline 
vs. Aldara-treated group, based on 2-way ANOVA followed by Bonferroni’s post hoc test. (b) Effect of the two 
different disease induction techniques for the development of the splenomegaly. Spleens were collected and 
weighted at the end of the experiment. Data are mean ± SEM for n = 15/group. **p < 0.01; ***p < 0.001, based 
on one-way ANOVA followed by Bonferroni’s post hoc test. OP: original protocol, MP: modified protocol.
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Distinctively, the animals used in the experiments did not show any sign of significant systemic disease, there-
fore, our novel method is ideally suitable to perform prolonged imiquimod treatment studies. Thus, it may poten-
tially contribute to the refinement of the IMQ model, to more accurately mimic the chronic nature of psoriasis, 
and also prove beneficial in further studies of psoriasis comorbidities.
Finally, our experimental approach may also be used in mouse model experiments with other topically applied 
drugs (such as TPA and acetone), to prevent the ingestion and the systemic consequences of these compounds.
In conclusion, our new method of using Finn chambers can be used to elicit the IMQ-induced psoriasiform 
dermatitis in mice without the systemic effects associated with the traditional technique.
Materials and Methods
Animals. Experiments were performed on female C57BL/6 mice (8–10 weeks, 20–25 g). The animals were 
bred and kept under standard pathogen-free conditions in the Laboratory Animal House of the Department of 
Pharmacology and Pharmacotherapy of the University of Pécs, at 24–25 °C, provided with food and water ad libi-
tum. All procedures were carried out according to the 1998/XXVIII Act of the Hungarian Parliament on Animal 
Protection and Consideration Decree of Scientific Procedures of Animal Experiments (243/1988). All experi-
ments were approved by the Ethics Committee on Animal Research of the University of Pécs, in full accordance 
to the Ethical Codex of Animal Experiments, and a license was assigned (license number: BA 02/2000-36/2017).
Induction of psoriasiform skin inflammation. The dorsal skin of mice was shaved using an electric 
shaver, and the remaining hairs were completely removed with depilatory cream one day prior to the first Aldara 
treatment. Two experimental paradigms were used for induction of psoriasiform dermatitis. In the original pro-
tocol (OP) group, 62.5 mg Aldara cream (5% IMQ) was applied on the shaved back skin of C57BL/6 mice on each 
day of the 4-day experiment1. In control animals, vaseline was used and in the same amount. In the modified 
protocol (MP) group, two Finn chambers (8 mm FinnChambers on Scanpor, SmartPractice, USA) were placed 
on the dorsal skin of each mouse, one filled with 25 mg Aldara, the other with 25 mg vaseline. Finn chambers 
were applied on the dorsal skin of mice for 8 hrs which proved to be sufficient for the complete penetration of the 
creams into the skin. Treatments were repeated over the next four days ensuring the same areas were treated daily. 
All procedures were done under ketamine (100 mg/kg i.p., Richter, Hungary) and xylazine (5 mg/kg i.p., Lavet, 
Hungary) anesthesia and at the end of the experiments, the anesthetized animals were sacrificed using cervical 
dislocation. Treated dorsal skin, spleen tissue and blood samples were all collected for further analysis.
Measurement of dorsal skin thickness. Double-fold dorsal skin thickness was measured and averaged 
at two distinct sites of the OP group, while the 8 mm treated areas were measured in the MP group using an engi-
neer’s micrometer (Moore and Wright, Sheffield, England) with 0.1 mm accuracy, prior to treatment with Aldara 
or control cream on each day of the experiments. Data were expressed as percent increase of back skin thickness 
compared with the initial values.
Measurement of blood perfusion changes. Blood perfusion was detected with Laser Speckle Contrast 
Analysis (LASCA) laser Doppler (Perimed, Sweden) method prior to the application of Aldara and vaseline 
on each day of the experiment. Measurements from this instrument are displayed as arbitrary perfusion units. 
Regions of interest (ROI) were selected according to the treated area on the dorsal skin (Aldara/vaseline treated 
whole back of OP group or the area covered by the Finn chambers in MP group) and mean perfusion was gen-
erated by PimSoft software (Perimed, Sweden). Data were expressed as percentage of blood perfusion change 
compared to the initial values.
Skin scaling score. The Aldara- or vaseline-treated dorsal skin area of C57BL/6 mice were evaluated daily by 
three trained dermatologists who were blinded for both experimental protocols. Skin scaling was scored, ranging 
from 0 to 4, as represented in the following: 0 – none, 1 – slight, 2 – moderate, 3 – marked, 4 – maximum.
Figure 5. MP method diminished the production of inflammatory cytokines in plasma samples. (a) IFN-α, 
(b) IL-1β, and (c) TNF-α cytokine concentration 6 hrs after the first IMQ treatment in the plasma samples 
of C57BL/6 mice. Data are mean ± SEM for n = 5/group. *p < 0.05; **p < 0.01, based on one-way ANOVA 
followed by Bonferroni’s post hoc test. OP: original protocol, MP: modified protocol.
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Histology. Excised dorsal skin tissue samples were formalin-fixed (6%) and embedded in paraffin, and 5 µm 
sections were cut and stained with hematoxylin-eosin for further histological analysis. Scoring parameters and 
values were determined on the basis of the signs characteristic to psoriasis at 200x magnification: (1) thickness 
of skin epidermal layer measured by AnalySIS software (2) Number of Munro’s microabscesses throughout the 
section.
Immunohistochemistry. 5 µm snap frozen tissue samples were sectioned by cryostat microtome. 
Endogenous peroxidase activity was blocked by incubation with 0.3% hydrogen peroxide for 15 min. Nonspecific 
secondary antibody binding was inhibited using BSA for 20 min. Tissue sections were incubated with rabbit poly-
clonal anti-mouse Ki-67 (AB9260, EMD Millipore Corporation, Temecula, CA, USA; 1:250), or rabbit polyclonal 
anti-mouse CD11b (NB110-89474, Novus Biologicals, CO 80112, USA; dilution 1:400) primary antibodies for 
1 hour at room temperature. This was followed by the incubation with horseradish peroxidase (HRP) conju-
gated secondary antibody for 30 min. Finally, visualization of target proteins was performed by diaminobenzidine 
development and nuclear staining with hematoxylin.
Measurement of proinflammatory cytokines. The concentration of proinflammatory cytokine TNF-α, 
IL-1β and IFN-α was measured from the peripheral blood samples collected 6 hours following the first Aldara 
treatment by ELISA method (Mouse TNF-α or IL-1β ELISA Set, catalogue number: 555268 or 559603, respec-
tively, BD Biosciences Eastern Europe, Heidelberg, Germany; Mouse IFN-α Platinum ELISA, catalogue number: 
BMS6027, Invitrogen, USA). The principal of the assay is to coat capture antibodies specific for the protein of 
interest onto the wells of a microplate. Standards and unknown samples are added into the plate. During the first 
incubation step, the antigen binds to the capture antibody. Following incubation, unbound proteins are removed 
by washing and a biotinylated detection antibody is added to the wells to form capture antibody-antigen-detection 
antibody complex. After the removal of unbound detection antibodies, streptavidin-HRP conjugate is added and 
binds to the biotinylated detection antibody. Following the last incubation and washing cycle to remove the 
unbound HRP conjugate, a substrate solution is added and is converted by the HRP enzyme to a detectable color 
product read by spectrophotometry. The color intensity is directly proportional to the concentration of antigen 
present in the unknown sample.
Statistical analysis. Results are expressed as mean ± S.E.M. Comparisons between Aldara- or 
vaseline-treated OP group and MP group were performed using a two-way ANOVA, followed by Bonferroni’s 
post hoc test for skin thickness, blood flow perfusion, skin scaling, and body weight. Splenomegaly, cytokine con-
centration and histology score data were evaluated by one-way ANOVA, followed by Bonferroni’s post hoc test. 
Statistical analysis was done using GraphPad Prism 5 for Windows (GraphPad Software, USA). Probability values 
p < 0.05 were regarded as significant.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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